Olaparib monotherapy is indicated for the treatment of adult patients with germline BRCA1/2 mutations, who have HER2-negative locally advanced or metastatic breast cancer. Patients should have previously been treated with an anthracycline and a taxane in the (neo)adjuvant or metastatic setting unless patients were not suitable for these treatments.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||29/03/2019|
|Rapid review completed||10/04/2019|
|Rapid Review outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of olaparib compared with the current standard of care.
The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.